Stage III NSCLC - is it time to centralize care?

Mackillop William J.; Booth Christopher M.

首页> 外文期刊>Nature reviews. Clinical oncology >Stage III NSCLC - is it time to centralize care?

【24h】

Stage III NSCLC - is it time to centralize care?

机译：III期NSCLC-是时候集中护理了吗？

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Eaton et al. report a very strong association between institutional clinical trial accrual volume and the survival of patients with stage III NSCLC. The observed volume effect might have been exaggerated by artefact. More work is required to quantify the volume effect and understand its causes, before rushing to centralize care.

机译：Eaton等。报告机构临床试验应计数量与III期NSCLC患者的生存率之间有很强的关联。观察到的体积效应可能已被伪影夸大了。在急于集中护理之前，需要更多的工作来量化数量效应并了解其原因。

著录项

来源
《Nature reviews. Clinical oncology 》 |2016年第11期| 共2页
作者
Mackillop William J.; Booth Christopher M.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学 ;
关键词

相似文献

外文文献
中文文献
专利

1. Stage III NSCLC - is it time to centralize care? [J] . Mackillop William J., Booth Christopher M. Nature reviews. Clinical oncology . 2016 ,第11期

机译：III期NSCLC-是时候集中护理了吗？
2. Pre- and postoperative care for stage I-III NSCLC: Which quality of care indicators are evidence-based? [J] . Numan Rachel C., Ten Berge Martijn, Burgers Jacobus A., Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2016 ,第Null期

机译：阶段I-III NSCLC的预先和术后护理：哪种质量的护理指标是基于证据？
3. Osimertinib Should be the Standard of Care for the Adjuvant Therapy of Stage IB to IIIA EGFR-Mutant NSCLC [J] . Remon Jordi, Hendriks Lizza E. L. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2021 ,第3期

机译：Osimertinib应该是阶段IB至IIIa EGFR-MUTANT NSCLC的辅助治疗的护理标准
4. Radiomic Features Predict Local Failure-free Survival in Stage Ⅲ NSCLC Adenocarcinoma Treated with Chemoradiation [C] . Jose Marcio Luna, Andrew R. Barsky, Russell T. Shinohara, Conference on Medical Imaging: Computer-Aided Diagnosis . 2021

机译：辐射瘤特征预测Ⅲ期NSCLC腺癌中的局部失效存活率
5. Pre-Treatment Radiomics Models for Clinical Outcomes in Early-Stage Non-Small Cell Lung Cancer (NSCLC) [D] . Shaffer, Nathan Allen. 2021

机译：早期非小细胞肺癌临床结果的预处理辐射瘤模型（NSCLC）
6. GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy [O] . Qing Zhou, Ming Chen, Gang Wu, 2020

机译：Gemstone-301：CS1001的III期临床试验作为局部晚期/不可切除（第III阶段）非小细胞肺癌（NSCLC）在先前同时/顺序化学疗法后没有疾病进展的患者的固结治疗
7. PCN43 THE ASSOCIATION OF TUMOR HISTOLOGY WITH FIRST-LINE TREATMENT AND LIFETIME MEDICAL-CARE COSTS AMONG ELDERLY STAGE IIIB/IV NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS TREATED WITH COMMONLY USED DOUBLET THERAPIES AMONG [O] . Lang K, Marciniak M, Faries D, 2008

机译：PCN43在IIIB / IV期非小细胞肺癌（NSCLC）老年患者中采用常用双盲疗法治疗的肿瘤组织学与一线治疗和终身医疗费用的关联

Stage III NSCLC - is it time to centralize care?

摘要

著录项

相似文献

相关主题

期刊订阅